Perrigo Co. Plc (PRGO)

Perrigo's stock price has experienced significant fluctuations in the past six months. On November 5, 2025, Perrigo reported third-quarter 2025 financial results, which led to a significant drop in the stock price. On February 26, 2026, Perrigo reported its fourth-quarter and fiscal year 2025 financial results from continuing operations, which saw the stock decline. On February 19, 2026, Perrigo announced a quarterly dividend. On March 3, 2026, Perrigo announced it would present at the UBS Global Consumer and Retail Conference, and the stock saw an increase. Perrigo is facing a class-action lawsuit for securities fraud related to its 2022 acquisition of Nestlé's infant formula plant and North American trademark rights, contributing to pessimistic market sentiment.

The healthcare sector, in which Perrigo operates, generally experiences a period of seasonal strength from April 25 to December 4. There is noted seasonality to EPS for Perrigo, which can complicate future predictions. Q1 and Q2 of 2026 are expected to be the bottom for Perrigo's earnings, with sequential improvements anticipated in Q3 and Q4. Products like cough/cold/allergy medications would experience higher demand during colder months and allergy seasons, while other products like skincare or digestive health might have more consistent demand or different seasonal peaks.

Perrigo Company plc (PRGO) is a global healthcare company focused on over-the-counter (OTC) health and wellness solutions. It operates in the healthcare sector, specifically the pharmaceuticals industry, emphasizing consumer self-care products. Perrigo has transitioned to a pure-play consumer self-care company, with two main segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment covers the United States, Canada, and Mexico, producing private-label versions of popular national brand products. The CSCI segment manages its consumer self-care business outside of the U.S. and Canada, primarily in Europe and Australia, emphasizing a branded consumer healthcare portfolio. Major product categories include upper respiratory, pain and sleep-aids, skincare and personal hygiene, digestive health, nutrition, and healthy lifestyle. Perrigo is legally headquartered in Dublin, Ireland, for tax purposes, while maintaining its operational headquarters in Grand Rapids, Michigan, U.S.

Perrigo Company plc has a significant global presence, with operations in more than 35 countries. Its primary markets are North America, Europe, and Australia, with additional key markets including Israel, Mexico, India, and China. Specific locations include Ireland (Dublin), United States (Allegan, Grand Rapids, and various other states), United Kingdom (Barnsley, Braunton, Leeds, Pimlico, and London), Australia (Balcatta), Israel (B'nei Brak, Ramat Hovav, Yad Eliyahu, Yeruham), Mexico (Ramos Arizpe, Col. Rosedal, Guadalajara), China (Shandong, Shanghai), and India (Ambernath).

Perrigo's brand reputation in the past year has been impacted by several events, leading to a degree of uncertainty in market sentiment. Perrigo is facing a class-action lawsuit for securities fraud in connection with its 2022 acquisition of Nestlé's infant formula plant. The company's third-quarter 2025 financial results showed weakness in the over-the-counter global market and challenges in the infant formula market, leading to a downward revision of its fiscal year 2025 outlook. The decision to conduct a strategic review of its infant formula business, announced in November 2025, indicates ongoing issues in this segment. Despite these challenges, Perrigo emphasizes its focus on accessible self-care solutions and reports gaining market share in several OTC store brand categories.

Institutional investors are the dominant force in Perrigo Company plc's ownership landscape, collectively holding approximately 87.43% of the company's stock. Major institutional owners include Price T Rowe Associates Inc /md/, BlackRock, Inc., and Vanguard Group Inc. Insider ownership, comprising executives and directors, typically ranges between 0.38% and 0.50% of outstanding shares. Michael J. Jandernoa is noted as the largest individual Perrigo shareholder, owning 41.51 million shares, representing 30.16% of the company. Moshe Arkin is another significant insider owner, holding 16.44% of the shares.